Figure 2.
Figure 2. SRC-3 deficiency significantly reduces the quiescence and increases the proliferation of HSCs. (A) Representative flow cytometric plots to show the cell-cycle distribution of LSK subpopulations in the BM of WT and SRC-3−/− mice. (B-D) Cell-cycle analysis of (B) LT-HSCs, (C) ST-HSCs, and (D) MPPs in the BM of WT and SRC-3−/− mice (n = 8 mice per group). (E-F) Flow cytometric analysis of in vivo BrdU incorporation of LT-HSCs, ST-HSCs, and MPPs from WT or SRC-3−/− BM (n = 6 mice per group). (G) qPCR analysis of cyclin-dependent kinase (CDK) inhibitors, cyclins, and CDKs in purified WT and SRC-3−/− LT-HSCs (n = 3 mice per group). All values are presented relative to WT controls. (H-I) Flow cytometric analysis of the percentages of LSKs in spleen (SP) and peripheral blood (PB) from WT and SRC-3−/− mice (n = 5 mice per group). *P < .05, **P < .01.

SRC-3 deficiency significantly reduces the quiescence and increases the proliferation of HSCs. (A) Representative flow cytometric plots to show the cell-cycle distribution of LSK subpopulations in the BM of WT and SRC-3−/− mice. (B-D) Cell-cycle analysis of (B) LT-HSCs, (C) ST-HSCs, and (D) MPPs in the BM of WT and SRC-3−/− mice (n = 8 mice per group). (E-F) Flow cytometric analysis of in vivo BrdU incorporation of LT-HSCs, ST-HSCs, and MPPs from WT or SRC-3−/− BM (n = 6 mice per group). (G) qPCR analysis of cyclin-dependent kinase (CDK) inhibitors, cyclins, and CDKs in purified WT and SRC-3−/− LT-HSCs (n = 3 mice per group). All values are presented relative to WT controls. (H-I) Flow cytometric analysis of the percentages of LSKs in spleen (SP) and peripheral blood (PB) from WT and SRC-3−/− mice (n = 5 mice per group). *P < .05, **P < .01.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal